ACS SensorsBiochemistryPeer-reviewed journal article
Ultrasensitive saliva-based detection of early Alzheimer's disease biomarkers via nanoparticle-enhanced evanescent scattering microscopy
Caterina DallariiD, Georg LadurneriD, Milana KendrisiciD, Federica Fenizi CariaiD, Claudia ManzliD, Luisa Ponticelli, Laura PeregoiD, Francesco GorettiiD, Caterina CrediiD, Manuela Prokesch, Adelheid Wöhrer, Bernhard BaumanniD, Rainer Andreas LeitgebiD, Francesco Saverio PavoneiD
- Citations
- 2
- FWCI
- 9.03
- Field percentile
- top 4%
Abstract
Alzheimers disease (AD) is the most common neurodegenerative disease, yet early diagnosis remains a major challenge. Current cerebrospinal fluid (CSF) assays are invasive and unsuitable for large-scale or repeated screening. Blood-based biomarkers have achieved sensitivities above 90%, but still face challenges of standardization, cost, technical complexity, and the need for sophisticated instrumentation. Saliva offers an attractive, non-invasive solution; however, the low concentrations of AD biomarkers have thus far hindered its clinical applicability. Here, we introduce a saliva-based diagnostic platform that combines Total Internal Reflection Scattering (TIRS) microscopy with antibody-functionalized metallic nanoparticles (NPs), for ultrasensitive, real-time quantification of salivary amyloid-{beta} (A{beta}) proteins. Using two established AD mouse models (APPsl and 5xFAD), we found that salivary A{beta}2 levels robustly distinguish transgenic from wild-type animals and correlate with brain amyloid deposition. Pooled and stratified analyses suggest these associations are primarily driven by the transgenic-wild-type contrast rather than linear changes within groups. Predictive modeling further confirmed diagnostic utility: in APPsl, Logistic Regression and Support Vector Machine (SVM) classifiers both achieved 92% accuracy with balanced sensitivity and specificity, while in 5xFAD, SVM reached 88% accuracy with perfect specificity. These results establish the NPs-enhanced TIRS sensor as a rapid, accurate and non-invasive tool for AD detection via saliva. By addressing a critical unmet need in neurodegenerative disease screening, this platform has strong potential to transform early diagnosis, enable timely interventions, and support biomarker-guided clinical trials. Its simplicity, speed, and scalability, make it well-suited for point-of-care diagnostics and large-scale screening initiatives. One Sentence SummaryUltrasensitive saliva test detects early Alzheimers biomarkers using nanoparticle-enhanced scattering microscopy
- organism: mouse
- assay: proteomics
- research focus: differential expression
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Olfactory neuroepithelium biomarker platform: a proof from Alzheimer's disease
Koko Ishizuka, Guanqun Shang, … Akira Sawa·bioRxiv·Oct 20, 2026
- Extracellular vesicles-based point-of-care testing for the diagnosis and monitoring of Alzheimer's disease
- Neurons as biosensors for discriminating neurological disorders in a brain-on-chip platform: Application to Alzheimer s Disease using patient CSF
Louise Miny, Jessica Rontard, … Isabelle Quadrio·bioRxiv·Aug 23, 2024
- A novel technology for objective, accurate and non-invasive early diagnosis and monitoring of Alzheimer’s disease in clinics and clinical trials
Kaveh Vejdani, Thomas Liebmann, … Padideh Kamali‐Zare·bioRxiv·Oct 2, 2019
- Advancing Early Diagnosis of Alzheimers Disease: A Paper-Based Aptasensor for Detecting Amyloid Beta(1-42) and p-tau181 from Plasma Using CdTe Quantum Dots
Elif Betül Balcı, Elif Nur Yildiz, … Umut Hasirci·bioRxiv·Jul 10, 2024
- Bridging Language Markers and Pathology: Correlations Between Digital Speech Measures and Surrogate CSF Biomarkers in Alzheimer's Disease
Yijiang Pang, Liu Chen, … Jiayu Zhou·Alzheimer s & Dementia Diagnosis Assessment & Disease MonitoringPeer-reviewed·Jul 1, 2026